In March 2026 we announced that Digistain has secured the rights to distribute geneType® across Southeast Asia. geneType is developed by Rhythm Biosciences, a publicly listed Australian company, and combines genetic data with clinical factors and family history to give a more comprehensive view of an individual’s risk of developing various cancers and chronic diseases.
Through our supply chain networks and commercial footprint in the region, we aim to make the geneType genetic test portfolio available to healthcare providers and patients across Southeast Asia.
Read Rhythm Biosciences’ announcement on its investor centre.
